| Mar 11, 2020
Search & Destroy: Chimeric Antigen Receptor T-Cells (CAR-T)
Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and they remain one of the hottest types of immunotherapies…more.
Categories: CAR-T Cell Therapy, General
